"The CryoValve SG aortic human heart valve may offer an attractive valve replacement option for many children with aortic valve disease. We plan to immediately begin conducting the bench and animal studies, as well as collecting the human clinical data necessary to apply for the HDE," said Steven G. Anderson, CryoLife's president and chief executive officer. "This HUD designation is an important first step toward expanding the use of our SynerGraft technology platform, which we believe is the foundation for the next generation of implantable biological tissues."
In February 2008, the Company received a 510(k) clearance from the FDA for its CryoValve® SG pulmonary human heart valve. The CryoValve SG pulmonary human heart valve is indicated for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures (RVOT), commonly performed in children with congenital heart defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG pulmonary human heart valve is then surgically implanted in place of the removed native pulmonary valve.
In August 2009, the Company received a 510(k) clearance from the FDA for its CryoPatch® SG pulmonary human cardiac patch. CryoPatch SG is indicated for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.
About CryoLife, Inc.
Founded in 1984, CryoLi
|SOURCE CryoLife, Inc.|
Copyright©2009 PR Newswire.
All rights reserved